ANCHIANO THERAP/S (ANCN) Reaches New 1-Year Low at $6.73

ANCHIANO THERAP/S (NASDAQ:ANCN) shares reached a new 52-week low during trading on Thursday . The stock traded as low as $6.73 and last traded at $7.47, with a volume of 200 shares changing hands. The stock had previously closed at $7.56.

Several research firms recently commented on ANCN. Oppenheimer assumed coverage on shares of ANCHIANO THERAP/S in a report on Monday. They issued an “outperform” rating and a $16.00 price target on the stock. LADENBURG THALM/SH SH assumed coverage on shares of ANCHIANO THERAP/S in a research report on Monday. They issued a “buy” rating for the company.

WARNING: This article was posted by Dakota Financial News and is the sole property of of Dakota Financial News. If you are accessing this article on another site, it was illegally copied and reposted in violation of US and international copyright legislation. The correct version of this article can be read at


Anchiano Therapeutics Ltd, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies to treat cancer-related diseases. It is primarily developing Inodiftagene vixteplasmid for the treatment of non-muscle-invasive bladder cancer. The company was formerly known as BioCancell Ltd.

Read More: Buy-Side Analysts

Receive News & Ratings for ANCHIANO THERAP/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANCHIANO THERAP/S and related companies with's FREE daily email newsletter.